Patient characteristics
. | Twice-daily MMF . | 3-times-daily MMF . |
|---|---|---|
| No. of patients | 38 | 47 |
| Mean age, y (range) | 52 (18-70) | 52 (17-67) |
| Bone marrow source (%) | 6 (16) | 0 |
| Recipients CMV seropositive (%)* | 20 (53) | 29 (62) |
| Disease, no. of patients | ||
| AML CR1 | 1 | 5 |
| AML > CR1 | 6 | 7 |
| MDS RA | 0 | 2 |
| MDS AML | 4 | 3 |
| ALL CR1 | 1 | 0 |
| ALL > CR1 | 2 | 0 |
| CML CP1 | 6 | 1 |
| CML > CP1 | 3 | 0 |
| CLL | 3 | 4 |
| Myelofibrosis | 2 | 2 |
| MM | 3 | 6 |
| NHL | 6 | 11 |
| HD | 1 | 6 |
. | Twice-daily MMF . | 3-times-daily MMF . |
|---|---|---|
| No. of patients | 38 | 47 |
| Mean age, y (range) | 52 (18-70) | 52 (17-67) |
| Bone marrow source (%) | 6 (16) | 0 |
| Recipients CMV seropositive (%)* | 20 (53) | 29 (62) |
| Disease, no. of patients | ||
| AML CR1 | 1 | 5 |
| AML > CR1 | 6 | 7 |
| MDS RA | 0 | 2 |
| MDS AML | 4 | 3 |
| ALL CR1 | 1 | 0 |
| ALL > CR1 | 2 | 0 |
| CML CP1 | 6 | 1 |
| CML > CP1 | 3 | 0 |
| CLL | 3 | 4 |
| Myelofibrosis | 2 | 2 |
| MM | 3 | 6 |
| NHL | 6 | 11 |
| HD | 1 | 6 |
MMF indicates mycophenolate mofetil; CMV, cytomegalovirus; AML, acute myeloid leukemia; CR1, first complete remission; MDS, myelodysplastic syndrome; RA, refractory anemia; ALL, acute lymphocytic leukemia; CML, chronic myelogenous leukemia; CP1, first chronic phase; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; and HD, Hodgkin disease.
For the CMV-seropositive patients with twice-daily MMF, 8 donors were CMV seropositive and 12 were seronegative. For the 29 CMV-seropositive 3-times-daily MMF patients, 7 donors were CMV seropositive and 22 were seronegative